It was a pleasure to speak with Dr Kim Papp (Probity Medical Research, Waterloo, ON, Canada) around the efficacy and tolerability of ruxolitinib cream in the treatment of atopic dermatitis (NCT03745638 & NCT03745651).
The abstract ‘Efficacy of Ruxolitinib Cream for the Treatment of Atopic Dermatitis by Baseline Clinical Characteristics: Pooled Subgroup Analysis From Two Randomized Phase 3 Studies‘ was presented at the AAD VMX, 23-25 April 2021.
- Could you give us a brief overview of the design of the TRuE-AD1 and TRuE-AD2 studies? (0:19)
- What did these studies teach us about the efficacy and tolerability of ruxolitinib cream in the treatment of atopic dermatitis? (1:03)
- What was the objective of the analysis you are presenting? (2:59)
- How well were the objectives met and what is the clinical significance of these findings? (4:28)
- Which patients are most likely to respond well to treatment with ruxolitinib cream? (7:58)
Disclosures: KAP has served as a consultant, speaker, clinical researcher, scientific officer, steering committee member, or advisor for AbbVie, Akros, Amgen, Anacor, Arcutis, Astellas, Avillion, Bausch Health/Valeant, Baxalta, Boehringer Ingelheim, Bristol-Myers Squibb, Can-Fite Biopharma, Celgene, Coherus, Dermavant, Dermira, Dice Pharmacueticals, Dow Pharma, Eli Lilly, Evelo, Galapagos, Galderma, Genentech, Gilead, GSK, Incyte, Janssen, Kyowa Hakko Kirin, Leo, Medimmune, Meiji Seika Pharma, Merck (MSD), Merck- Serono, Mitsubishi Pharma, Moberg Pharma, Novartis, Pfizer, PRCL Research, Regeneron, Roche, Sanofi-Aventis/Genzyme, Sun Pharma, Takeda, UCB and Xencor.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the AAD VMX 2021.
Share this Video
Related Videos In Atopic Dermatitis
Gil Yosipovitch, EADV 2022: Lebrikizumab Monotherapy for Moderate to Severe Atopic Dermatitis
ADvocate 1 (NCT04146363) and ADvocate 2 (NCT04178967) are phase 3, randomised, double-blind, placebo-controlled trials, investigating lebrikizumab monotherapy in moderate to severe atopic dermatitis. touchIMMUNOLOGY caught up with Prof. Gil Yosipovitch (Miller School of Medicine, University of Miami, Miami, FL, USA) around the ADvocate 1 and ADvocate 2 phase 3 studies and the findings from his […]
Laura Carucci, EAACI 2022: Probiotic L.rhamnosus GG in Paediatric Atopic Dermatitis – Findings from the ProPAD Study
Paediatric atopic dermatitis is a common chronic skin condition in children that results in dry, itchy skin. It was a pleasure to talk with Dr. Laura Carucci (University of Naples Federico II. Naples, Italy) to discuss the aims, outcome measures and findings from the ProPAD study, investigating L.rhamnosus GG in paediatric atopic dermatitis. The abstract […]
Laura Carucci, EAACI 2022: Health Burden of Paediatric Atopic Dermatitis and Impact of Probiotic Treatment
Paediatric atopic dermatitis is a common chronic skin condition in children that results in dry, itchy skin. It was a pleasure to talk with Dr. Laura Carucci (University of Naples Federico II. Naples, Italy) to discuss the health burden of paediatric atopic dermatitis, the unmet needs in treatment and the potential of probiotic treatment. The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!